|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF,
Gao ZH and Qu XJ: Des-gamma-carboxy prothrombin antagonizes the
effects of Sorafenib on human hepatocellular carcinoma through
activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Oncotarget. 7:36767–36782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Methylation-mediated repression
of microRNA-129-2 suppresses cell aggressiveness by inhibiting high
mobility group box 1 in human hepatocellular carcinoma. Oncotarget.
7:36909–36923. 2016.PubMed/NCBI
|
|
9
|
Yang W, Dou C, Wang Y, Jia Y, Li C, Zheng
X and Tu K: MicroRNA-92a contributes to tumor growth of human
hepatocellular carcinoma by targeting FBXW7. Oncol Rep.
34:2576–2584. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu CY, Lin KY, Tien MT, Wu CT, Uen YH and
Tseng TL: Frequent DNA methylation of MiR-129-2 and its potential
clinical implication in hepatocellular carcinoma. Genes Chromosomes
Cancer. 52:636–643. 2013.PubMed/NCBI
|
|
11
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Ren F, Rong M, Luo Y, Dang Y and
Chen G: Association between underexpression of microrna-203 and
clinicopathological significance in hepatocellular carcinoma
tissues. Cancer Cell Int. 15:622015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alpini G, Glaser SS, Zhang JP, Francis H,
Han Y, Gong J, Stokes A, Francis T, Hughart N, Hubble L, et al:
Regulation of placenta growth factor by microRNA-125b in
hepatocellular cancer. J Hepatol. 55:1339–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Coulouarn C, Factor VM, Andersen JB,
Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver
cancer correlates with suppression of the hepatic phenotype and
gain of metastatic properties. Oncogene. 28:3526–3536. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gramantieri L, Ferracin M, Fornari F,
Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E,
Grazi GL, et al: Cyclin G1 is a target of miR-122a, a microRNA
frequently down-regulated in human hepatocellular carcinoma. Cancer
Res. 67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin CJ, Gong HY, Tseng HC, Wang WL and Wu
JL: miR-122 targets an anti-apoptotic gene, Bcl-w, in human
hepatocellular carcinoma cell lines. Biochem Biophys Res Commun.
375:315–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greer EL and Brunet A: FOXO transcription
factors at the interface between longevity and tumor suppression.
Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hartmann W, Küchler J, Koch A, Friedrichs
N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, et
al: Activation of phosphatidylinositol-3′-kinase/AKT signaling is
essential in hepatoblastoma survival. Clin Cancer Res.
15:4538–4545. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nogueira V, Park Y, Chen CC, Xu PZ, Chen
ML, Tonic I, Unterman T and Hay N: Akt determines replicative
senescence and oxidative or oncogenic premature senescence and
sensitizes cells to oxidative apoptosis. Cancer Cell. 14:458–470.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gospodarowicz MK, Brierley JD and
Wittekind C: TNM classifcation of malignant tumours. 8th edition.
John Wiley & Sons; Oxford, UK: 2017
|
|
21
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
22
|
Miyoshi A, Kitajima Y, Sumi K, Sato K,
Hagiwara A, Koga Y and Miyazaki K: Snail and SIP1 increase cancer
invasion by upregulating MMP family in hepatocellular carcinoma
cells. Br J Cancer. 90:1265–1273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J,
Tang ZY and Zeng ZC: MicroRNA-34a expression levels in serum and
intratumoral tissue can predict bone metastasis in patients with
hepatocellular carcinoma. Oncotarget. 7:87246–87256. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dou C, Wang Y, Li C, Liu Z, Jia Y, Li Q,
Yang W, Yao Y, Liu Q and Tu K: MicroRNA-212 suppresses tumor growth
of human hepatocellular carcinoma by targeting FOXA1. Oncotarget.
6:13216–13228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Machida S, Spangenburg EE and Booth FW:
Forkhead transcription factor FoxO1 transduces insulin-like growth
factor's signal to p27Kip1 in primary skeletal muscle satellite
cells. J Cell Physiol. 196:523–531. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim SJ, Winter K, Nian C, Tsuneoka M, Koda
Y and McIntosh CH: Glucose-dependent insulinotropic polypeptide
(GIP) stimulation of pancreatic beta-cell survival is dependent
upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)
signaling, inactivation of the forkhead transcription factor Foxo1,
and down-regulation of bax expression. J Biol Chem.
280:22297–22307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grinius L, Kessler C, Schroeder J and
Handwerger S: Forkhead transcription factor FOXO1A is critical for
induction of human decidualization. J Endocrinol. 189:179–187.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie L, Ushmorov A, Leithäuser F, Guan H,
Steidl C, Färbinger J, Pelzer C, Vogel MJ, Maier HJ, Gascoyne RD,
et al: FOXO1 is a tumor suppressor in classical Hodgkin lymphoma.
Blood. 119:3503–3511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu Y, Elshimali Y, Sarkissyan M, Mohamed
H, Clayton S and Vadgama JV: Expression of FOXO1 is associated with
GATA3 and Annexin-1 and predicts disease-free survival in breast
cancer. Am J Cancer Res. 2:104–115. 2012.PubMed/NCBI
|
|
31
|
Rena G, Guo S, Cichy SC, Unterman TG and
Cohen P: Phosphorylation of the transcription factor forkhead
family member FKHR by protein kinase B. J Biol Chem.
274:17179–17183. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: Inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong XY, Chen C, Sun X, Guo P, Vessella
RL, Wang RX, Chung LW, Zhou W and Dong JT: FOXO1A is a candidate
for the 13q14 tumor suppressor gene inhibiting androgen receptor
signaling in prostate cancer. Cancer Res. 66:6998–7006. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calnan DR and Brunet A: The FoxO code.
Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang H and Tindall DJ: FOXO factors: A
matter of life and death. Future Oncol. 2:83–89. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Furukawa-Hibi Y, Yoshida-Araki K, Ohta T,
Ikeda K and Motoyama N: FOXO forkhead transcription factors induce
G2-M checkpoint in response to oxidative stress. J Biol
Chem. 277:26729–26732. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arden KC: FoxOs in tumor suppression and
stem cell maintenance. Cell. 128:235–237. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ichiyama K, Gonzalez-Martin A, Kim BS, Jin
HY, Jin W, Xu W, Sabouri-Ghomi M, Xu S, Zheng P, Xiao C and Dong C:
The MicroRNA-183-96-182 cluster promotes T helper 17 cell
pathogenicity by negatively regulating transcription factor Foxo1
expression. Immunity. 44:1284–1298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haflidadóttir BS, Larne O, Martin M,
Persson M, Edsjö A, Bjartell A and Ceder Y: Upregulation of miR-96
enhances cellular proliferation of prostate cancer cells through
FOXO1. PLoS One. 8:e724002013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu Z, Sun H, Zeng W, He J and Mao X:
Upregulation of MircoRNA-370 induces proliferation in human
prostate cancer cells by downregulating the transcription factor
FOXO1. PLoS One. 7:e458252012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
